EXEL – exelixis, inc. (US:NASDAQ)

News

Exelixis: The Double Backbone Potential Of CABOMETYX And Zanzalintinib [Seeking Alpha]
Exelixis: Stable Demand And High Margins With Undervalued Shares [Seeking Alpha]
RBC Capital Lowers Exelixis (EXEL) Price Target to $43 [Yahoo! Finance]
Exelixis (EXEL) was upgraded by Truist Financial Corporation to "strong-buy".
Exelixis (EXEL) Valuation After Earnings Beat FDA Progress And Cabometyx Label Expansion [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com